Silo Pharma raises about $815,000 in private placement at $1.50 per share
Archived — this story has rotated out of today’s deck. It is kept here in full.
The gist
Silo Pharma closed a private placement of 136,005 shares at $1.50 and pre-funded warrants, expecting about $815,000 in net proceeds.
The micro-cap biotech's stock trades below the offering price and is down 82.6% over the past year.
Background
Silo Pharma, Inc. is a NASDAQ-listed micro-cap biotechnology firm trading under the ticker SILO. It closed a private placement with accredited investors, issuing common shares and pre-funded warrants, with proceeds earmarked for working capital and general corporate purposes. The raise comes as the stock trades below the offering price and has fallen sharply over the past year.
How it unfolded
- Nov 6, 2026Silo Pharma closed a private placement with accredited investors, issuing 136,005 common shares at $1.50 per share and pre-funded warrants to purchase up to 430,661 shares at $1.4999 per warrant.
- Nov 6, 2026The company said it expects net proceeds of approximately $815,000 for working capital and general corporate purposes; MarketScreener reported the company received $0.849956 million in funding.
- Nov 6, 2026At the close, SILO traded at $1.33, below the $1.50 offering price, with shares down 82.6% over the past year and a market cap of $2.05 million.
Key terms
- private placement
- A funding round in which securities are sold privately to a small number of chosen investors rather than through a public offering.
- pre-funded warrants
- A financial security giving its holder the right to buy or sell stock at a fixed strike price.
- micro-cap
- The total market value of a publicly traded company's outstanding shares owned by stockholders.
Source: Wikipedia
Who’s saying what
- Analysts
- Investing.com/InvestingPro analysis said Silo Pharma holds more cash than debt and has liquid assets exceeding short-term obligations, though the company remains unprofitable, and identified the stock as undervalued based on its Fair Value analysis.
Still unverified
The expected net proceeds of approximately $815,000 are stated as an expectation after deducting placement agent fees and expenses.